Det foreliggende forordningsforslag og de to direktiver indeholder også et krav til den farmaceutiske industri om, at den set i lyset af de næsten optimale rammebetingelser - bilagsbeskyttelsen er intetsteds så høj som i Europa - beviser sin innovationsevne.
The proposal for a regulation and the two directives before us do, however, at the same time demand that the pharmaceutical industry, in view of the almost ideal framework conditions - data exclusivity standards are nowhere else as high as in Europe - should demonstrate its capacity for innovation.